13F reference period
Q2 2026
Security Snapshot
Universe Pharmaceuticals INC - Class A ordinary shares (UPC) Institutional Ownership
CUSIP: G9442G138
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
4
Shares (Excl. Options)
37.45K
Full value: 37,453 · shares · 30 Jun 2026Price
$6.10
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A ordinary shares
- Symbol
- UPC on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 37,453
- Total 13F value
- $228,361
- Portfolio coverage rank
- 0%
- Share change
- +37,453
- Value change
- +$228,361
- Number of holders
- 4
- Shares outstanding
- 5,009,225
- SEC-reported price per share
- $4.27
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- UPC - Universe Pharmaceuticals INC - Class A ordinary shares is tracked under CUSIP G9442G138.
- 4 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 0 to 4 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $0 to .
$228.36K
Full value: $228,361 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 4 institutions filings for Q2 2026.
Security key
G9442G138
13F reference period
Q2 2026
13F holders
4
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
UPC full holder history
Universe Pharmaceuticals INC SEC filings
Universe Pharmaceuticals INC company facts
Universe Pharmaceuticals INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G9442G138:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
UPC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Ye Piao | 18% | $5,555,560 | 916,759 | Origin Force Intelligence Limited | 27 Jul 2026 | |||
| Zheng Chunhua | 10% | $3,029,552 | 499,926 | Orbis BioCapital Limited | 27 Jul 2026 | |||
| Tang Chengming | 10% | $3,026,509 | 499,424 | Whitmore Limited | 27 Jul 2026 | |||
| Xie Shan | 10% | $3,026,509 | 499,424 | Horizon Ridge Limited | 27 Jul 2026 | |||
| Lu Shanshan | 10% | $3,023,467 | 498,922 | Meridian Prosperous Limited | 30 Jul 2026 | |||
| Yang Lu (nmn) | 10% | $3,023,467 | 498,922 | Clever Way Global Limited | 27 Jul 2026 | |||
| Chen Xuncheng | 9.9% | $3,017,377 | 497,917 | Star Voyage International Limited | 27 Jul 2026 | |||
| Li Xuefeng | 9.3% | $2,819,463 | 465,258 | August Luck Global Limited | 27 Jul 2026 | |||
| SABBY MANAGEMENT, LLC | 4.9% | $117,504 | 28,111 | SABBY MANAGEMENT, LLC | 31 Dec 2025 |
As of 30 Jun 2026,
4
institutional investors reported holding
shares of
Universe Pharmaceuticals INC - Class A ordinary shares (UPC).
This represents
0.75%
of the company’s total
outstanding shares.
37.45K
Full value: 37,453 · shares · 30 Jun 20265.01M
Full value: 5,009,225 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 44,531 | $191,483 | +$191,483 | $4.30 | 1 |
| 2026 Q2 | 37,453 | $228,361 | +$228,361 | $6.10 | 4 |
| 2026 Q1 | 0 | $0 | -$3,604 | $4.27 | 0 |
| 2025 Q4 | 946 | $3,604 | -$5,440 | $3.81 | 1 |
| 2025 Q3 | 2,001 | $9,044 | +$9,044 | $4.26 | 2 |
| 2025 Q2 | 0 | $0 | -$1,091 | $4.27 | 0 |
| 2025 Q1 | 266 | $1,091 | +$1,091 | $4.10 | 1 |